ArticleOncology letters2014
A two-microRNA signature as a potential biomarker for early gastric cancer.
Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- PLASMA: Partial LeAst Squares for Multiomics Analysis.Cancers · 2025Article
- Article
- Evaluation of the Rock1 and microRNA-148a expression in biopsies collected from patients with Helicobacter pylori induced gastritis.BMC gastroenterology · 2024Article
- Comprehensive analysis of disulfidptosis related genes and prognosis of gastric cancer.World journal of clinical oncology · 2023Article
- Prognostic value of expression levels of miR-148a, miR-152 and HLA-G in colon cancer.Oncology letters · 2022Article
- Targeted MicroRNA Profiling in Gastric Cancer with Clinical Assessement.Balkan journal of medical genetics : BJMG · 2021Article
- Micro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- The diagnostic and prognostic values of microRNA-196a in cancer.Bioscience reports · 2021Article
- Cyclin-Dependent Kinase 1 (CDK1) is Co-Expressed with CDCA5: Their Functions in Gastric Cancer Cell Line MGC-803.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- A robust qualitative transcriptional signature for the correct pathological diagnosis of gastric cancer.Journal of translational medicine · 2019Article
- miR-148a regulates expression of the transferrin receptor 1 in hepatocellular carcinoma.Scientific reports · 2019Article
- Article
- Biomarkers for classification and class prediction of stress in a murine model of chronic subordination stress.PloS one · 2018Article
- Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.International journal of hematology · 2017Article
- miR-564 is downregulated in gastric carcinoma and targets E2F3.Oncology letters · 2017Article
- Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells.Turkish journal of biology = Turk biyoloji dergisi · 2017Article
- The role of microRNA-196a in tumorigenesis, tumor progression, and prognosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- miR-148a downregulates the expression of transforming growth factor-β2 and SMAD2 in gastric cancer.International journal of oncology · 2016Article
- The Role of Mir-148a in Cancer.Journal of Cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most common malignant tumors worldwide. No fundamental improvements in the five-year survival rates of patients with GC have been reported due to a low early diagnosis rate. Therefore, the identification of novel biomarkers is urgently required for an early diagnosis of GC. A total of 86 patients were selected for the present study, including 44 patients with early stage GC (T1-T2 according to TNM staging criteria) and 42 normal gastric mucosa samples from non-cancer patients as controls. A total of 18 samples were used for the microRNA (miRNA) microarray experiments, including nine early GC and nine normal gastric mucosa samples. Bioinformatics algorithms, significant analysis of microarray (SAM), top scoring pair (TSP) and statistical receiver operating characteristic curves were used to identify the best signatures. Finally, quantitative PCR was used to validate the candidate biomarkers for early gastric cancer in the test samples (35 cancer and 33 normal samples). Using the SAM algorithm, 14 differential miRNAs were selected as candidate biomarkers. Using the TSP algorithm, hsa-miR-196a and hsa-miR-148a were obtained as a signature to differentiate between the early GC and normal samples. A coincidental result was observed in the test samples. hsa-miR-196a was upregulated and hsa-miR-148a was downregulated in the early GC samples. hsa-miR-196a and hsa-miR-148a have the potential to serve as candidate biomarkers for early GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.